All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in adults Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10191895" target="_blank" >RIV/00179906:_____/13:10191895 - isvavai.cz</a>

  • Alternative codes found

    RIV/60162694:G44__/13:43875052

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in adults Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults

  • Original language description

    Background: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. Discussion: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agendaof national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and thefuture place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age. Results: The use of c

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FN - Epidemiology, infection diseases and clinical immunology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Central European Journal of Public Health

  • ISSN

    1210-7778

  • e-ISSN

  • Volume of the periodical

    21

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    5

  • Pages from-to

    233-237

  • UT code for WoS article

    000329004200013

  • EID of the result in the Scopus database